Aarti Drugs Targets 55–60% Sayakha Utilization in June

Aarti Drugs Limited — Q4 & FY26 Earnings Call (FY ended 31 Mar 2026; call dated 18 May 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly highlights “sharp sequential recovery in Q4 FY ’26” and “significantly improved momentum.”
• They project improving utilization and profitability drivers (Sayakha ramp-up, pricing stabilization, regulated/export mix) with multiple quantitative targets (e.g., utilization, EBITDA margin range).

2. Key Themes from Management Commentary

• Macro/industry headwinds easing sequentially: Elevated freight/energy/input costs, raw material inconsistency due to West Asia war; management says the business exited the year “on a much stronger footing.”
• Pricing stabilization since Sep 2025: “pricing trends started stabilizing from September 2025 onwards,” expected to improve realizations short run.
• Utilization ramp-up as the core lever:
• Sayakha methylamines plant ramp-up progress: March 2026 “nearly 1,000 tonnes per month,” with further utilization progress expected in FY27.
• Structural mix shift toward regulated/export markets: Exports contribution rose (FY25 35% → FY26 38%); regulated market contribution rose (66% → 73%).
• Formulations growth driven by exports/non-antibiotic momentum: Formulations revenue up 41% YoY in Q4; exports are 69% of formulation revenue.
• Salicylic acid remains a drag but is being actively addressed: Production was shut due to variable losses; restart tied to equipment/process improvements and derivatives ramp.

3. Q&A Analysis

Theme A: Sayakha (methylamines) ramp-up & integration

• Core questions:
• How is the methylamine plant ramping (utilization trajectory, integration reached)?
• What to expect over the next 2 years?
• Management response:
• Started Sep 2025; utilization ~29% in Dec quarter, ~40% in March quarter; missed target due to ammonia-based raw material constraints from West Asia war.
• Guidance: June quarter 55–60%, and >70% utilization within a year.
• Also linked Sayakha utilization to metformin expansion (more metformin = more captive demand).
• Notable signals:
• Clear, time-bound ramp targets (55–60% in June; >70% in ~12 months).
• Acknowledges external constraint (raw material) but frames ramp as “going pretty well.”

Theme B: Salicylic acid profitability, restart timing, and margin path

• Core questions:
• Why profitability lagged; what EBITDA/margin impact was in the prior quarter?
• When and how will salicylic acid restart?
• Management response:
• Salicylic acid “still remains a laggard”; they shut production due to variable losses from inability to reduce raw material cost (equipment delay).
• Restart depends on installing/operating improvements; also pursuing forward integration of salicylic acid derivatives and antidumping.
• Additional operational detail: phenol recovery equipment, effluent cost improvements, derivatives plant timing (end of May / mid-June), and labor shortage causing delay.
• Evasive/partial elements:
• They do not give a clean “restart date” but provide a multi-pronged plan and equipment-driven logic.
• EBITDA loss quantified only as a rough combined figure later (see Theme F).

Theme C: FY27 growth expectations (volume vs price) and antibiotic demand risk

• Core questions:
• Should investors expect ~10–12% volume growth and positive rate variance?
• Why company-level volume growth guidance is only 8–10% vs internal 10–15%?
• Antibiotic segment outlook: recovery vs risk from elevated prices?
• Management response:
• They “strive for achieving a volume growth of 8% to 10%” (internal target 10–15%).
• They tie upside to persistence of elevated API prices due to West Asia war; downside risk is domestic antibiotic demand if crude/API prices stay “too high.”
• Antibiotics: sequential recovery (March vs Dec), but elevated prices could hurt domestic demand; they expect price growth and volumes “probably can be a bit flattish.”
• Notable signals:
• Explicit demand elasticity narrative: “If the API become very expensive… demand… goes down” (citing 2023 Russia-Ukraine war behavior).

Theme D: Margin trajectory (gross margin/EBITDA) and flow-through

• Core questions:
• With realizations up but input costs up, should gross margin move?
• Will higher absolute gross profit translate to better EBITDA?
• Is 13.5–14% EBITDA margin target realistic given uncertainties?
• Management response:
• “We don’t expect much movement in gross margins” but want to maintain Q4 gross margin; manufacturing cost reduction of ~1% could help EBITDA.
• They acknowledge a key tradeoff: if API prices rise too high, gross margin % can lower even if absolute gross profit rises.
• FY27 EBITDA margin target: 13.5% to 14% (war uncertainty acknowledged; earlier target was 14%–14.5%).
• They also target +100 to +200 bps gross contribution improvement (explicitly in one answer).
• Evasive/partial elements:
• They avoid a precise consolidated gross margin % for FY27, preferring ranges and conditional statements.

Theme E: Formulations growth drivers & run-rate sustainability

• Core questions:
• What is driving formulation growth if oncology dossiers are still in approval?
• Can the ~INR90 crore run-rate be maintained in FY27?
• Management response:
• Growth is driven by direct exports in non-oncology portfolio and approvals/market extensions in regulated markets.
• Oncology plant is “pre-revenue,” but they expect approvals and market extensions to keep export growth pace.
• They confirm: “INR90 crores run rate… possible to maintain in FY ’27.”
• Notable signals:
• Strong confirmation on run-rate sustainability despite oncology being pre-revenue.

Theme F: Capex, CWIP, debt, and ramp-up losses

• Core questions:
• Capex beyond INR300–400 crore (and whether it matches cash generation).
• What is CWIP of INR214 crores related to?
• Total EBITDA loss from new projects in FY26.
• Management response:
• Capex: INR300–400 crore over next 2–3 years; “safe capex” (brownfield/quasi-greenfield). Potential to fine-tune upward if cash flows improve.
• CWIP INR214 crore: part cogen boiler + brownfield expansions; major portion tied to formulation R&D/oncology dossiers; amortization timing depends on approvals.
• FY26 EBITDA loss from new projects: rough estimate INR18–20 crores.
• Credibility note:
• They provide numbers but with “rough estimate” language; still, the capex framework is consistent with prior calls (see section 7).

4. Guidance / Outlook

Explicit guidance (quantitative)

• Sayakha utilization:
• June quarter: 55–60%
• Within ~1 year: >70% utilization
• Sayakha production rate (observed):
• March 2026: ~1,000 tonnes/month
• FY27 EBITDA margin target: 13.5% to 14%
• War-free earlier target: 14% to 14.5% (reduced due to uncertainty)
• FY27 gross contribution improvement: at least +100 bps (and question implied 100–200 bps; management agreed “at least 100 bps”)
• FY27 volume growth aspiration: management “strive” 8–10%; internal 10–15%
• Capex: INR300–400 crore over next 2–3 years
• Formulations run-rate: ~INR90 crore maintainable in FY27 (confirmed)
• EBITDA loss from new projects in FY26: INR18–20 crores (rough)

Implicit signals (qualitative)

• Pricing environment: API prices “stable” and “pricing trends stabilizing since Sep 2025”; further increases depend on crude (they cite thresholds).
• Regulated market ramp: US/EU flow expected within 12–18 months for certain API flows; regulated contribution expected to keep scaling.
• Antibiotic demand risk: Elevated crude/API prices could suppress domestic antibiotic demand; volumes may be flattish while prices rise.

5. Standout Statements (directly revealing)

• Sequential recovery narrative: “business exited the year on a much stronger footing with a sharp sequential recovery in Q4 FY ’26.”
• Sayakha ramp targets + external constraint: utilization missed 45–50% targets “mainly because of ammonia-based raw materials in that plant because of the West Asia war,” but June quarter expected 55–60%.
• Salicylic acid shut-down rationale: “we took a call to shut that production” due to “variable losses… because we were not able to recover and reduce the raw material cost.”
• Antibiotic demand elasticity risk: “If the crude remains too high… more than $110, $120, then probably… it might affect the domestic demand of antibiotics.”
• FY27 margin reset due to war: “Had this war not been there, our earlier targets were definitely 14% to 14.5% EBITDA margin for FY 2027.”
• Formulations run-rate confidence: “INR90 crores run rate… possible to maintain in FY ’27.”
• Capex flexibility: “if at all… more lucrative, probably we might end up replacing some of the capex” and “fine-tune” based on cash flows.

6. Red Flags / Positive Signals

Red flags
– War/crude dependence is repeatedly used as a swing factor (margin and demand). Guidance is therefore conditional.
– Salicylic acid remains unresolved: shut production, restart depends on equipment/process changes; multiple operational constraints (effluent, labor shortage, antidumping).
– Some targets are “aspirational/rough” (e.g., EBITDA loss estimate, margin improvement assumptions).
– Volume growth guidance is conservative vs internal targets (8–10% vs 10–15%), implying uncertainty in demand or mix.

Positive signals
– Clear operational milestones with dates (Sayakha utilization targets; derivatives plant timing; metformin DMF filed; FDA inspection intent).
– Mix shift to regulated markets is quantified (regulated contribution 66% → 73%).
– Formulations export-led growth is confirmed with run-rate maintenance.
– Debt position described as improving (debt-to-equity “historically lowest” in Q4).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q2 FY26 (Nov 2025): Optimistic but more “progress/early signs” language; margins improving; export robust; ramp-up early.
• Q3 FY26 (Feb 2026): More cautious—explicitly cited low utilization, shipment delays from China, voluntary shutdown, and greenfield ramp below optimal; still claimed “inflection point.”
• Q4 FY26 (May 2026): Tone becomes more optimistic: “sharp sequential recovery,” “pricing stabilization,” “significantly improved momentum,” and more confident FY27 targets.
• Classification shift: More Optimistic (from Q3’s headwind-heavy framing to Q4’s recovery + clearer ramp milestones).

b. Tracking Past Commitments vs Outcomes

1. Sayakha ramp-up expectation (Q3 FY26 call):
2. Past: expected ramp to “nearly 50% by March and April 2026.”
3. Current: March quarter utilization achieved ~40%, with June quarter 55–60% and >70% within a year.

4. Flag: ⏳ Delayed (hit ~40% vs ~50% target; recovery expected next quarter).

5. Salicylic acid stabilization / EBITDA positive threshold (Q3 FY26 call):

6. Past: “turn EBITDA positive once it crosses around 800 tons per month.”
7. Current: salicylic acid still a “laggard,” production shut due to variable losses; restart tied to equipment/process improvements; derivatives plant delayed by labor shortage.

8. Flag: ❌ Missed / Dropped (no evidence of EBITDA-positive run; narrative moved to restart readiness rather than achieved threshold).

9. Pricing stabilization from Sep 2025 (Q3 FY26 call):

10. Past: “prices have stabilized from September onwards.”
11. Current: reiterates stabilization and says recovery strengthened in Q4; also “prices are now stable” in Q&A.

12. Flag: ✅ Delivered / Consistent.

13. FY27 EBITDA margin target (Q3 FY26 call):

14. Past (Nov/Feb calls): management discussed targets like 14%–15% steady state and sequential improvement toward 15%–16%.
15. Current: FY27 target 13.5%–14% (explicitly reduced due to war).
16. Flag: ⏳ Delayed / Reduced (not necessarily missed, but guidance is more conservative than earlier “sunny day” aspirations).

c. Narrative Shifts

• From “operational disruptions” to “operational execution”: Q3 emphasized delays/shutdowns/low utilization; Q4 emphasizes ramp-up progress and sequential recovery.
• Salicylic acid narrative worsened in specificity: earlier it was progressing toward EBITDA positivity; now it’s shut and being restarted with a multi-pronged fix (phenol recovery, effluent, antidumping, derivatives).
• Regulated market emphasis increased: Q4 quantifies regulated contribution growth and provides more concrete US/EU flow expectations.

d. Consistency & Credibility Signals

• Credibility: Medium
• Positives: management provides utilization targets and ties misses to specific external causes (ammonia/raw material due to war).
• Negatives: salicylic acid milestones appear to slip materially; FY27 margin target is reduced vs earlier “sunny” levels; some answers remain conditional on crude/war duration.

e. Evolution of Key Themes

• Demand: Antibiotics risk becomes more explicit in Q4 (domestic demand sensitivity to crude/API prices).
• Margins: Shift from “margin pressure due to utilization + disruptions” (Q3) to “maintain gross margin; EBITDA improvement via utilization and mix” (Q4), but with war-driven uncertainty.
• Expansion/Integration: Sayakha ramp is the dominant execution theme; salicylic acid is the main unresolved execution risk.
• Regulated markets: Increasingly central and quantified in Q4.

f. Additional Insights (cross-period intelligence)

• The company is using crude/war as both upside and downside lever—upside for realizations, downside for domestic antibiotic demand and margin % dynamics. This can mask underlying execution risk (especially salicylic acid) by attributing outcomes to macro.
• Utilization targets are moving forward quarter-by-quarter (Sayakha: ~29% → ~40% → 55–60% next), suggesting management is actively managing expectations rather than abandoning them—generally positive, but it also confirms ramp is not yet at steady state.